KRAS G12D MUTATIONS
Clinical trials for KRAS G12D MUTATIONS explained in plain language.
Never miss a new study
Get alerted when new KRAS G12D MUTATIONS trials appear
Sign up with your email to follow new studies for KRAS G12D MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough pancreatic cancer: targeted drug trial launches
Disease control Recruiting nowThis study tests an experimental drug called RNK08954 in 60 adults with advanced pancreatic cancer that has spread and has a specific genetic change (KRAS G12D). The goal is to see if the drug can shrink tumors or slow the cancer's growth, and to check for side effects. Participa…
Matched conditions: KRAS G12D MUTATIONS
Phase: PHASE2 • Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Recruiting nowThis study tests a new drug called GFH375 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe, how the body processes it, and whether it can shrink tumors. About 407 adults aged 18 to 75 with advanced c…
Matched conditions: KRAS G12D MUTATIONS
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 26, 2026 03:53 UTC